pioneer 6 semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN and 6 | Cardiovascular Diabetology Topline Data for Oral Semaglutide

These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the risks that are discussed more fully in our filings with the Securities and Exchange Commission (the SEC) including the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 24, 2026, and other documents we subsequently file with or furnish to the SEC, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 12, 2026

Maintenance planning begins including gradual dose titration down, transition to lifestyle-based management, or low-dose maintenance therapy

If youre in your late 30s, 40s, or 50s and youre experiencing period changes like the following, perimenopause could be the reason why: Irregular periods Shorter or longer periods Lighter or heavier periods These changes are caused by a drop in estrogen and progesterone levels

Tirzepatide | Drugs | BNF NICE

The SELECT trial (NEJM, 2023) demonstrated that semaglutide 2.4mg reduced major adverse cardiovascular events (MACE) by 20% in over 17,000 patients with overweight/obesity and established cardiovascular disease, without diabetes